Nausea and vomiting are common problems for cancer patients. Half of them will experience
these symptoms during the course of their disease, either because of the cancer itself or
because of their treatment1. They are ranked by patients as two of the worst adverse effects
of cancer chemotherapy and cause a negative impact on patient's functional, emotional, social
and nutritional status and quality of life2,3.
Nowadays, a wide variety of antiemetic agents are available for the prevention and treatment
of CINV. In this scenario, three classes play a critical role: Selective 5-HT3-receptor
antagonists - approved for clinical practice in early 1990s, revolutionized the management of
CINV representing the most effective agents in the treatment of acute emesis -,
Corticosteroids - with unknown mechanism of action, effective when administered as single
agents in patients receiving chemotherapy of low emetic potential but are most beneficial
when used in combination with other antiemetic agents, potentiating their anti-emetic
efficacy in both acute and delayed symptoms - and neurokinin 1 receptor antagonist - also
effective against both acute and delayed emesis, but restricted utility in daily clinical
practice because of its high cost.